Please visit answersincme.com/XWC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology, discusses immunotherapy-based combination regimens for the first-line treatment of unresectable HCC. Upon completion of this activity, participants should be better able to: Recognize the therapeutic rationale for immunotherapy-based combination treatment regimens for the management of unresectable hepatocellular carcinoma (HCC) in the first-line setting; Review the clinical implications of the latest efficacy and safety data for immunotherapy-based combination regimens for the first-line treatment of unresectable HCC; and Describe patient selection strategies for available first-line combination immunotherapy-based regimens in unresectable HCC.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related